SIP
STML

Stoneridge Investment Partners’s Stemline Therapeutics, Inc. STML Stock Holding History

Stoneridge Investment Partners’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-25,323
Closed -$217K – 336
2017
Q1 		$217K Sell
25,323
-8,402
-25% -$76.6K 0.03% 279
2016
Q4 		$361K Hold
33,725
– – 0.05% 238
2016
Q3 		$365K Sell
33,725
-165
-0.5% -$1.34K 0.05% 226
2016
Q2 		$229K Hold
33,890
– – 0.03% 246
2016
Q1 		$158K Sell
33,890
-13,814
-29% -$67.5K 0.02% 274
2015
Q4 		$301K Sell
47,704
-6,166
-11% -$50K 0.04% 239
2015
Q3 		$476K Sell
53,870
-800
-1% -$8.39K 0.07% 203
2015
Q2 		$643K Buy
54,670
+15,738
+40% +$219K 0.08% 190
2015
Q1 		$563K Buy
38,932
+14,743
+61% +$226K 0.07% 198
2014
Q4 		$413K Buy
24,189
+4,790
+25% +$69.1K 0.05% 203
2014
Q3 		$242K Buy
19,399
+5,304
+38% +$65.3K 0.04% 214
2014
Q2 		$207K Sell
14,095
-250
-2% -$3.83K 0.03% 210
2014
Q1 		$292K Sell
14,345
-8,488
-37% -$206K 0.06% 162
2013
Q4 		$448K Buy
+22,833
New +$609K 0.09% 128

Other funds holding STML

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
IBT
International Biotechnology Trust London, United Kingdom $297M AUM 17.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Stoneridge Investment Partners's STML Position: Q2 2017 in Review

Stoneridge Investment Partners sold out of Stemline Therapeutics, Inc. (STML) in Q2 2017, closing a stake of 25,323 shares — an estimated $217K sold.

Stoneridge Investment Partners first reported a position in STML in Q4 2013 and held it in 14 quarters. The position peaked at $643K in Q2 2015. 70 funds tracked by Wall St. Rank hold STML as of Q2 2017.

  • Stoneridge Investment Partners reported no remaining Stemline Therapeutics, Inc. position as of Q2 2017 after selling out during the quarter.
  • Stoneridge Investment Partners sold 25,323 Stemline Therapeutics, Inc. shares in Q2 2017, an estimated $217K.
  • Stoneridge Investment Partners first reported a position in Stemline Therapeutics, Inc. in Q4 2013 and held it in 14 quarters.
  • Stoneridge Investment Partners's Stemline Therapeutics, Inc. position peaked at $643K in Q2 2015.
  • 70 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2017.

Based on Stoneridge Investment Partners's 13F filing for Q2 2017, filed 1 Aug 2017.